18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
复制标题
DOI：
10.1007/s11886-013-0370-6
复制
发表时间：
2013-04-01
影响因子：
3.7
通讯作者：
Dorbala, Sharmila
中科院分区：
文献类型：
--
作者：
Skali, Hicham;Schulman, Allison R.;Dorbala, Sharmila
心脏受累预示结节病患者预后不良。然而，由于心脏结节病的非特异性临床表现，斑片状心肌受累，以及诊断试验的诊断率有限，心脏结节病的早期诊断非常困难。因此，没有标准化的方法来早期诊断心脏结节病。能够识别疾病和预测治疗反应的成像方式对于改善心脏结节病的管理至关重要。F-18-FDG PET在评估心脏结节病患者的疾病活动性和监测治疗反应方面具有许多实用优势。越来越多的数据支持F-18-氟脱氧葡萄糖（18F-FDG）PET在心脏结节病患者的诊断和风险分层中发挥越来越大的作用。
Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. F-18-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of F-18-fluorodeoxyglucose (18F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.